ArticleInternational journal of nanomedicine2020
Macrophage Membrane-Coated Nanoparticles Alleviate Hepatic Ischemia-Reperfusion Injury Caused by Orthotopic Liver Transplantation by Neutralizing Endotoxin.
Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 50 citations in OpenAlex.
- Chemokine-Guided Biomimetic Mn/Ce Nanozymes for Immunomodulation and Cardioprotection in Doxorubicin-Induced Cardiomyopathy.Advanced healthcare materials · 2026Article
- Macrophage polarization in ischemia-reperfusion injury: from molecular mechanisms to therapeutic strategies.Frontiers in immunology · 2026Review
- Nanomedicine in Organ Transplantation: From Graft Preservation and Repair to Immunomodulation and Monitoring.Theranostics · 2026Review
- Research status and advances in dexmedetomidine for sepsis‑induced multiple organ dysfunction syndrome (Review).International journal of molecular medicine · 2025Review
- Macrophage membrane coated nanoscale coordination polymers promote graft survival in allogeneic transplantation.Journal of nanobiotechnology · 2025Article
- The novel GSDMD inhibitor GI-Y2 exerts antipyroptotic effects to reduce atherosclerosis.Clinical and translational medicine · 2025Article
- Mechanism of engineered macrophage membrane bionic gene-carrying nanospheres for targeted drug delivery to promote wound repair in deep second-degree burns.Scientific reports · 2025Article
- BMAL1 deficiency in macrophages exacerbates sepsis-induced inflammatory response and organ damage by regulating PGC-1α.American journal of clinical and experimental immunology · 2025Article
- Macrophage Membrane-Coated Nanocarriers in Myocardial Infarction: A Paradigm Shift in Targeted Cardiac Therapy.International journal of nanomedicine · 2025Review
- Application of targeted drug delivery by cell membrane-based biomimetic nanoparticles for inflammatory diseases and cancers.European journal of medical research · 2024Review
- Macrophage-Mimicking Cellular Nanoparticles Scavenge Proinflammatory Cytokines in Specimens of Patients with Inflammatory Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- De novo design of a nanoregulator for the dynamic restoration of ovarian tissue in cryopreservation and transplantation.Journal of nanobiotechnology · 2024Review
- The Prospect of Biomimetic Immune Cell Membrane-Coated Nanomedicines for Treatment of Serious Bacterial Infections and Sepsis.The Journal of pharmacology and experimental therapeutics · 2024Review
- Engineered macrophage-biomimetic versatile nanoantidotes for inflammation-targeted therapy against Alzheimer's disease by neurotoxin neutralization and immune recognition suppression.Bioactive materials · 2023Article
- Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment.Journal of nanobiotechnology · 2022Review
- Pro-efferocytic macrophage membrane biomimetic nanoparticles for the synergistic treatment of atherosclerosis via competition effect.Journal of nanobiotechnology · 2022Article
- Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury.Materials today. Bio · 2022Article
- Engineered Cell Membrane-Derived Nanoparticles in Immune Modulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Cepharanthine loaded nanoparticles coated with macrophage membranes for lung inflammation therapy.Drug delivery · 2021Article
- Cell-derived extracellular vesicles and membranes for tissue repair.Journal of nanobiotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the effect and mechanism of macrophage membrane-coated nanoparticles (M-NPs) on hepatic ischemia-reperfusion injury (I/RI) caused by orthotopic liver transplantation. In addition, the advantages of TLR4 MATERIALS AND
methodsWe prepared biomimetic M-NPs and identified their characteristics. M-NPs were injected into an SD rat model of orthotopic liver transplantation, and the anti-inflammatory and anti-I/RI activities of M-NPs were studied in vivo and in vitro. In addition, we overexpressed macrophage membrane Toll-like receptor 4 (TLR4) in vitro and prepared TLR4+/M-NPs. Then, we assessed the characteristics and advantages of TLR4+/M-NPs.
resultsThe M-NPs neutralized endotoxin, inhibited the overactivation of Kupffer cells (KCs) and suppressed the secretion of inflammatory factors by inhibiting the endotoxin-mediated TLR4/MyD88/IRAK1/NF-κB signaling pathway. In an orthotopic liver transplantation model in SD rats, M-NPs showed significant therapeutic efficacy by neutralizing endotoxin and suppressing the secretion of inflammatory factors. Moreover, overexpression of TLR4 on the macrophage membrane by using a TLR4
conclusionThis study indicates that M-NPs can effectively alleviate I/RI induced by liver transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.